Literature DB >> 27208160

MMP-9 signaling in the left ventricle following myocardial infarction.

Rugmani Padmanabhan Iyer1, Mira Jung1, Merry L Lindsey2.   

Abstract

Following myocardial infarction (MI), the left ventricle (LV) undergoes a series of cardiac wound healing responses that involve both the stimulation of robust inflammation to clear necrotic myocytes and tissue debris and the induction of extracellular matrix (ECM) protein synthesis to generate an infarct scar. The collective changes in myocardial structure and function are termed LV remodeling, and matrix metalloproteinase-9 (MMP-9) is a key instigator of post-MI LV remodeling. Through direct molecular effects on ECM and inflammatory protein turnover as well as indirect effects on major cell types that coordinate cardiac wound healing, namely the infiltrating leukocytes and the cardiac fibroblasts, MMP-9 coordinates multiple aspects of LV remodeling. In this review, we will discuss recent research that has expanded our understanding of post-MI LV remodeling, including recent proteomic advances focused on the ECM compartment to provide novel functional and translational insights. This overview will summarize how our understanding of MMP-9 has evolved over the last decade and will provide insight into future directions that will drive our understanding of MMP-9-directed cardiac ECM turnover in the post-MI LV.

Entities:  

Keywords:  extracellular matrix; matrix metalloproteinases-9; proteomics; signaling; transcription factors

Mesh:

Substances:

Year:  2016        PMID: 27208160      PMCID: PMC4967202          DOI: 10.1152/ajpheart.00243.2016

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  107 in total

Review 1.  Temporal and spatial expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases following myocardial infarction.

Authors:  Merry L Lindsey; Rogelio Zamilpa
Journal:  Cardiovasc Ther       Date:  2010-07-14       Impact factor: 3.023

Review 2.  Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.

Authors:  Rajeshwar P Verma; Corwin Hansch
Journal:  Bioorg Med Chem       Date:  2007-01-17       Impact factor: 3.641

Review 3.  Crosstalk between fibroblasts and inflammatory cells.

Authors:  Sophie Van Linthout; Kapka Miteva; Carsten Tschöpe
Journal:  Cardiovasc Res       Date:  2014-04-11       Impact factor: 10.787

4.  Oxidation of CaMKII determines the cardiotoxic effects of aldosterone.

Authors:  B Julie He; Mei-Ling A Joiner; Madhu V Singh; Elizabeth D Luczak; Paari Dominic Swaminathan; Olha M Koval; William Kutschke; Chantal Allamargot; Jinying Yang; Xiaoqun Guan; Kathy Zimmerman; Isabella M Grumbach; Robert M Weiss; Douglas R Spitz; Curt D Sigmund; W Matthijs Blankesteijn; Stephane Heymans; Peter J Mohler; Mark E Anderson
Journal:  Nat Med       Date:  2011-11-13       Impact factor: 53.440

Review 5.  Monocyte and macrophage contributions to cardiac remodeling.

Authors:  Maarten Hulsmans; Flora Sam; Matthias Nahrendorf
Journal:  J Mol Cell Cardiol       Date:  2015-11-21       Impact factor: 5.000

Review 6.  Matrix metalloproteinases and myocardial infarction.

Authors:  Wannakorn Phatharajaree; Arintaya Phrommintikul; Nipon Chattipakorn
Journal:  Can J Cardiol       Date:  2007-07       Impact factor: 5.223

7.  Lipopolysaccharide decreases single immunoglobulin interleukin-1 receptor-related molecule (SIGIRR) expression by suppressing specificity protein 1 (Sp1) via the Toll-like receptor 4 (TLR4)-p38 pathway in monocytes and neutrophils.

Authors:  Keiko Ueno-Shuto; Kosuke Kato; Yukihiro Tasaki; Miki Sato; Keizo Sato; Yuji Uchida; Hiromichi Sakai; Tomomi Ono; Mary Ann Suico; Kazunori Mitsutake; Naofumi Tokutomi; Hirofumi Kai; Tsuyoshi Shuto
Journal:  J Biol Chem       Date:  2014-05-12       Impact factor: 5.157

Review 8.  Macrophage roles following myocardial infarction.

Authors:  Jessica M Lambert; Elizabeth F Lopez; Merry L Lindsey
Journal:  Int J Cardiol       Date:  2008-07-25       Impact factor: 4.164

9.  Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo.

Authors:  J Xu; D Rodriguez; E Petitclerc; J J Kim; M Hangai; Y S Moon; G E Davis; P C Brooks; S M Yuen
Journal:  J Cell Biol       Date:  2001-09-03       Impact factor: 10.539

10.  Contrasting Inflammation Resolution during Atherosclerosis and Post Myocardial Infarction at the Level of Monocyte/Macrophage Phagocytic Clearance.

Authors:  Edward B Thorp
Journal:  Front Immunol       Date:  2012-03-12       Impact factor: 7.561

View more
  40 in total

1.  Application of Hybrid Matrix Metalloproteinase-Targeted and Dynamic 201Tl Single-Photon Emission Computed Tomography/Computed Tomography Imaging for Evaluation of Early Post-Myocardial Infarction Remodeling.

Authors:  Stephanie L Thorn; Shayne C Barlow; Attila Feher; Mitchel R Stacy; Heather Doviak; Julia Jacobs; Kia Zellars; Jennifer M Renaud; Ran Klein; Robert A deKemp; Aarif Y Khakoo; TaeWeon Lee; Francis G Spinale; Albert J Sinusas
Journal:  Circ Cardiovasc Imaging       Date:  2019-11-11       Impact factor: 7.792

2.  MMP9 inhibition increases autophagic flux in chronic heart failure.

Authors:  Shyam S Nandi; Kenichi Katsurada; Neeru M Sharma; Daniel R Anderson; Sushil K Mahata; Kaushik P Patel
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-10-16       Impact factor: 4.733

3.  Early matrix metalloproteinase-9 inhibition post-myocardial infarction worsens cardiac dysfunction by delaying inflammation resolution.

Authors:  Rugmani Padmanabhan Iyer; Lisandra E de Castro Brás; Nicolle L Patterson; Manishabrata Bhowmick; Elizabeth R Flynn; Majdouline Asher; Presley L Cannon; Kristine Y Deleon-Pennell; Gregg B Fields; Merry L Lindsey
Journal:  J Mol Cell Cardiol       Date:  2016-10-13       Impact factor: 5.000

4.  Inflammation in myocardial injury: mesenchymal stem cells as potential immunomodulators.

Authors:  Weiang Yan; Ejlal Abu-El-Rub; Sekaran Saravanan; Lorrie A Kirshenbaum; Rakesh C Arora; Sanjiv Dhingra
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-05-24       Impact factor: 4.733

5.  Cardiac fibroblast activation during myocardial infarction wound healing: Fibroblast polarization after MI.

Authors:  Michael J Daseke; Mavis A A Tenkorang; Upendra Chalise; Shelby R Konfrst; Merry L Lindsey
Journal:  Matrix Biol       Date:  2020-05-21       Impact factor: 11.583

6.  The compendium of matrix metalloproteinase expression in the left ventricle of mice following myocardial infarction.

Authors:  Amanda R Kaminski; Edwin T Moore; Michael J Daseke; Fritz M Valerio; Elizabeth R Flynn; Merry L Lindsey
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-02-21       Impact factor: 4.733

7.  Investigation of association of genetic variant rs3918242 of matrix metalloproteinase-9 with hypertension, myocardial infarction and progression of ventricular dysfunction in Irish Caucasian patients with diabetes: a report from the STOP-HF follow-up programme.

Authors:  Chris Watson; J Paul Spiers; Max Waterstone; Adam Russell-Hallinan; Joseph Gallagher; Kenneth McDonald; Cristin Ryan; John Gilmer; Mark Ledwidge
Journal:  BMC Cardiovasc Disord       Date:  2021-02-12       Impact factor: 2.298

Review 8.  Proteomic analysis of the cardiac extracellular matrix: clinical research applications.

Authors:  Merry L Lindsey; Mira Jung; Michael E Hall; Kristine Y DeLeon-Pennell
Journal:  Expert Rev Proteomics       Date:  2018-01-09       Impact factor: 3.940

9.  Macrophage overexpression of matrix metalloproteinase-9 in aged mice improves diastolic physiology and cardiac wound healing after myocardial infarction.

Authors:  Cesar A Meschiari; Mira Jung; Rugmani Padmanabhan Iyer; Andriy Yabluchanskiy; Hiroe Toba; Michael R Garrett; Merry L Lindsey
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-10-13       Impact factor: 4.733

Review 10.  Assigning matrix metalloproteinase roles in ischaemic cardiac remodelling.

Authors:  Merry L Lindsey
Journal:  Nat Rev Cardiol       Date:  2018-08       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.